Details

Improving the histologic detection of DSA-negative antibody-mediated rejection in kidney transplants
ID Hidalgo, Luis G. (Author), ID Arnol, Miha (Author), ID Kojc, Nika (Author), ID Večerić-Haler, Željka (Author), ID Halloran, Philip F (Author), et al.

.pdfPDF - Presentation file, Download (2,47 MB)
MD5: 945050CA962CDA9C441E173C598C5771
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S1600613525029430 This link opens in a new window

Abstract
Emerging treatments for antibody-mediated rejection (ABMR, NEJM391(2):122-132) have increased the importance of ABMR detection when donor-specific antibody (DSA) is negative. We addressed this issue in the Trifecta-Kidney study (ClinicalTrials.gov #NCT04239703) using three centralized tests in 690 kidney transplant biopsies: DSA (One Lambda Inc.), blood donor-derived cell-free DNA (dd-cfDNA, Prospera™ test, Natera, Inc.), and molecular biopsy assessment (MMDx). We used an “AutoBanff 2022” algorithm to model the impact of alternative DSA interpretations on the histologic diagnosis of “DSA-negative” ABMR following Banff guidelines, including agreement with dd-cfDNA and molecular ABMR. Lowering MFI cutoffs for DSA-positivity did not improve detection of DSA-negative ABMR. However, simply calling all DSA positive allowed Banff 2022 guidelines to identify 46% more ABMR cases with no measurable DSA, and per Net Reclassification Improvement increased agreement between histologic diagnoses and both dd-cfDNA (P=7.72E-7) and molecular ABMR (P=7.69E-7). New ABMR cases were as strongly positive for dd-cfDNA and molecular ABMR as those found using the conventional DSA interpretation. A validation set analysis using INTERCOMEX study data (ClinicalTrials.gov NCT#01299168) confirmed these findings, and found that the new DSA-negative ABMR cases identified by calling all DSA positive had the same risk for graft loss as those found with conventional DSA interpretation.

Language:English
Keywords:donor-derived cell-free DNA, kidney biopsy, donor-specific antibody, microarrays antibody-mediated rejection, kidney transplant rejection
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2026
Number of pages:Str. 117-130
Numbering:Vol. 26, iss. 1
PID:20.500.12556/RUL-181417 This link opens in a new window
UDC:616.61
ISSN on article:1600-6143
DOI:10.1016/j.ajt.2025.08.029 This link opens in a new window
COBISS.SI-ID:246735107 This link opens in a new window
Publication date in RUL:07.04.2026
Views:336
Downloads:211
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:American journal of transplantation
Shortened title:Am. j. transplant.
Publisher:Elsevier, American Society of Transplantation & American Society of Transplant Surgeons
ISSN:1600-6143
COBISS.SI-ID:24071897 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Projects

Funder:Natera, Inc
Acronym:Trifecta-Kidney

Funder:Transcriptome Sciences Inc
Acronym:Trifecta-Kidney

Funder:Alberta Transplant Applied Genomics Centre
Acronym:Trifecta-Kidney

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back